A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT02264574 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

229

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small-Cell Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Obinutuzumab
DRUG: Chlorambucil

Sponsor

Pharmacyclics LLC.